These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 17297453)
1. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453 [TBL] [Abstract][Full Text] [Related]
2. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976 [TBL] [Abstract][Full Text] [Related]
3. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640 [TBL] [Abstract][Full Text] [Related]
4. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Roberts CG; Millar EK; O'Toole SA; McNeil CM; Lehrbach GM; Pinese M; Tobelmann P; McCloy RA; Musgrove EA; Sutherland RL; Butt AJ Oncogene; 2011 Jul; 30(28):3186-97. PubMed ID: 21383694 [TBL] [Abstract][Full Text] [Related]
5. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771 [TBL] [Abstract][Full Text] [Related]
6. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644 [TBL] [Abstract][Full Text] [Related]
7. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106 [TBL] [Abstract][Full Text] [Related]
8. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells. Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368 [TBL] [Abstract][Full Text] [Related]
9. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Raha P; Thomas S; Thurn KT; Park J; Munster PN Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915 [TBL] [Abstract][Full Text] [Related]
10. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling. Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736 [TBL] [Abstract][Full Text] [Related]
11. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer. Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986 [TBL] [Abstract][Full Text] [Related]
12. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121 [TBL] [Abstract][Full Text] [Related]
13. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Marsaud V; Gougelet A; Maillard S; Renoir JM Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746 [TBL] [Abstract][Full Text] [Related]
14. Up-regulated A20 promotes proliferation, regulates cell cycle progression and induces chemotherapy resistance of acute lymphoblastic leukemia cells. Chen S; Xing H; Li S; Yu J; Li H; Liu S; Tian Z; Tang K; Rao Q; Wang M; Wang J Leuk Res; 2015 Sep; 39(9):976-83. PubMed ID: 26159495 [TBL] [Abstract][Full Text] [Related]
15. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells. Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334 [TBL] [Abstract][Full Text] [Related]
16. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells. Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049 [TBL] [Abstract][Full Text] [Related]
17. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance. Pitta CA; Papageorgis P; Charalambous C; Constantinou AI Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064 [TBL] [Abstract][Full Text] [Related]
18. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer. Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998 [TBL] [Abstract][Full Text] [Related]
19. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. Osipo C; Gajdos C; Cheng D; Jordan VC J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267 [TBL] [Abstract][Full Text] [Related]
20. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]